FES PET changed nodal staging, field design and boost dose in ER-positive breast cancer
In a diagnostically difficult breast cancer case, FES PET identified occult ER-positive nodal disease and materially changed radiotherapy volume and dose.
Tag
Breast
Patients with documented fatigue were less likely to complete electronic symptom surveys after breast RT
Patients with clinician-documented fatigue had 39% lower odds of completing electronic fatigue assessments, exposing an important limitation of PRO-only monitoring.
ALTJ V35Gy above 50% tripled lymphedema risk after breast radiotherapy
Irradiating more than half of the axillary-lateral thoracic junction to 35 Gy was independently associated with a threefold higher lymphedema risk.
Dose–LET hotspots were associated with capsular contracture after proton postmastectomy radiotherapy
Combined high-dose and high-LET exposure around breast implants was associated with severe capsular contracture after proton postmastectomy radiotherapy.
Higher immune-cell radiation dose was associated with worse breast cancer-specific survival
Each 1-Gy increase in estimated immune-cell dose was associated with 66% higher breast cancer mortality after multivariable adjustment.
KROG 19-09 reveals major dose variation within intended breast nodal treatment groups
Substantial physician-dependent dose variation meant treatment-group assignment did not consistently reflect the dose actually delivered to regional nodes.
Radiotherapy was not associated with longer survival in breast cancer leptomeningeal disease
In 232 women with breast cancer leptomeningeal disease, radiotherapy was not associated with longer overall survival, while systemic therapy was.
Bullous pemphigoid developed during breast radiotherapy with concurrent pembrolizumab
Bullous pemphigoid emerged after seven radiotherapy fractions during pembrolizumab, spreading beyond the treatment field and ultimately preventing completion of both therapies.
Baseline extracellular-vesicle microRNAs were associated with breast radiotherapy toxicity
Baseline miR-144-5p and miR-222-3p differed in patients who later developed greater radiation toxicity, but the signals require validation.
Protons produced greater subclinical lung changes after breast nodal irradiation
Proton therapy produced greater CT-detected lung changes than photons despite lower lung dose and no increase in clinical pulmonary toxicity.
FLASH altered early molecular responses without improving breast cell survival
Electron FLASH changed DNA-damage, transcriptomic, cytokine, and microtubule responses but did not alter clonogenic survival under normoxic conditions.
Stereotactic radiotherapy plus atezolizumab missed the AZTEC efficacy target
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Three-week locoregional breast radiotherapy was noninferior for arm lymphedema
40 Gy in 15 fractions did not increase three-year arm lymphedema or compromise recurrence and mortality outcomes compared with 50 Gy.
Different factors predicted cardiac-event subtypes after hypofractionated breast radiotherapy
Planning-CT calcification and age predicted atherosclerotic events, while anthracyclines and respiratory toxicity predicted other cardiac complications.
Surface guidance matched skin marks for breast setup and reduced positioning variability
Single-camera surface guidance provided comparable mean setup accuracy with less variability, while intrafraction breast motion remained below 3 mm in most observations.